USD securities
USD fixed-income securities
| Issuer | Amount (in millions) | Coupon | Maturity |
| Novartis Securities Investment Ltd. | 3,000 | 5.125% | 2019 |
| Novartis Capital Corp. | 1,000 | 1.800% | 2020 |
| Novartis Capital Corp. | 1,000 | 4.400% | 2020 |
| Novartis Capital Corp. | 1,000 | 2.400% | 2022 |
| Novartis Capital Corp. | 1,500 | 2.400% | 2022 |
| Novartis Capital Corp. | 2,150 | 3.400% | 2024 |
| Novartis Capital Corp. | 1,750 | 3.000% | 2025 |
| Novartis Capital Corp. | 1,000 | 3.100% | 2027 |
| Novartis Capital Corp. | 500 | 3.700% | 2042 |
| Novartis Capital Corp. | 1,850 | 4.400% | 2044 |
| Novartis Capital Corp. | 1,250 | 4.000% | 2045 |
Credit ratings of Novartis AG
| Moody’s Investors Service | S&P Global Ratings | Fitch Ratings | |
| Short term | P-1 | A-1+ | F1+ |
| Long term | A1 | AA- | AA |
| Outlook | Stable | Stable | Negative |
Novartis Securities Investment Ltd.
| Principal amount | USD 3,000,000,000 |
| ISIN | US66989GAA85 |
| Issuer | Novartis Securities Investment Ltd., Bermuda |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 5.125% |
| Coupon payment date | February 10, August 10 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 10, 2009 |
| Issue price | 99.822 |
| Maturity date | February 10, 2019 |
| Joint book-runners | JP Morgan, Bank of America, Citi, Goldman Sachs |
| Bloomberg | NOVNVX 5.125 02/10/19 |
Novartis Capital Corp.
| Principal amount | USD 1,000,000,000 |
| ISIN | US66989HAL24 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 1.800% |
| Coupon payment date | February 14 and August 14, commencing August 14, 2017 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 17, 2017 |
| Issue price | 99.609 |
| Maturity date | February 14, 2020 |
| Joint book-runners | Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS |
| Bloomberg | NOVNVX 1.8 02/14/2020 |
Novartis Capital Corp.
| Principal amount | USD 1,000,000,000 |
| ISIN | US66989HAD08 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 4.400% |
| Coupon payment date | April 24 and October 24, commencing October 24, 2010 |
| Documentation | SEC registered shelf registration |
| First settlement date | March 16, 2010 |
| Issue price | 99.237 |
| Maturity date | April 24, 2020 |
| Joint book-runners | Goldman Sachs, JP Morgan, Bank of America Merrill Lynch, Barclays, Citi, Morgan Stanley |
| Bloomberg | NOVNVX 4.4 04/24/20 |
Novartis Capital Corp.
| Principal amount | USD 1,000,000,000 |
| ISIN | US66989HAM07 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 2.400% |
| Coupon payment date | May 17 and November 17, commencing May 17, 2017 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 17, 2017 |
| Issue price | 99.449 |
| Maturity date | May 17, 2022 |
| Joint book-runners | Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS |
| Bloomberg | NOVNVX 2.4 05/17/2022 |
Novartis Capital Corp.
| Principal amount | USD 1,500,000,000 |
| ISIN | US66989HAE80 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 2.400% |
| Coupon payment date | March 21 and September 21, commencing March 21, 2013 |
| Documentation | SEC registered shelf registration |
| First settlement date | September 21, 2012 |
| Issue price | 99.225 |
| Maturity date | September 21, 2022 |
| Joint book-runners | JP Morgan, Morgan Stanley, BNP Paribas, Citi, Bank of America Merrill Lynch, UBS |
| Bloomberg | NOVNVX 2.4 09/21/22 |
Novartis Capital Corp.
| Principal amount | USD 2,150,000,000 |
| ISIN | US66989HAG39 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 3.400% |
| Coupon payment date | May 6 and November 6, commencing May 6, 2014 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 21, 2014 |
| Issue price | 99.287 |
| Maturity date | May 6, 2024 |
| Joint book-runners | Goldman Sachs, Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, JP Morgan |
| Bloomberg | NOVNVX 3.4 05/06/24 |
Novartis Capital Corp.
| Principal amount | USD 1,750,000,000 |
| ISIN | US66989HAJ77 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 3.000% |
| Coupon payment date | May 20 and November 20, commencing May 20, 2016 |
| Documentation | SEC registered shelf registration |
| First settlement date | November 20, 2015 |
| Issue price | 99.010 |
| Maturity date | November 20, 2025 |
| Joint book-runners | Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS |
| Bloomberg | NOVNVX 3 11/20/2025 |
Novartis Capital Corp.
| Principal amount | USD 1,000,000,000 |
| ISIN | US66989HAN89 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 3.100% |
| Coupon payment date | May 17 and November 17, commencing May 17, 2017 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 17, 2017 |
| Issue price | 99.109 |
| Maturity date | May 17, 2027 |
| Joint book-runners | Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS |
| Bloomberg | NOVNVX 3.1 05/17/2027 |
Novartis Capital Corp.
| Principal amount | USD 500,000,000 |
| ISIN | US66989HAF55 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 3.700% |
| Coupon payment date | March 21 and September 21, commencing March 21, 2013 |
| Documentation | SEC registered shelf registration |
| First settlement date | September 21, 2012 |
| Issue price | 98.325 |
| Maturity date | September 21, 2042 |
| Joint book-runners | JP Morgan, Morgan Stanley, BNP Paribas, Citi, Bank of America Merrill Lynch, UBS |
| Bloomberg | NOVNVX 3.7 09/21/42 |
Novartis Capital Corp.
| Principal amount | USD 1,850,000,000 |
| ISIN | US66989HAH12 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 4.400% |
| Coupon payment date | May 6 and November 6, commencing May 6, 2014 |
| Documentation | SEC registered shelf registration |
| First settlement date | February 21, 2014 |
| Issue price | 99.196 |
| Maturity date | May 6, 2044 |
| Joint book-runners | Goldman Sachs, Bank of America Merrill Lynch, Barclays, Citi, Credit Suisse, Deutsche Bank, JP Morgan |
| Bloomberg | NOVNVX 4.4 05/06/44 |
Novartis Capital Corp.
| Principal amount | USD 1,250,000,000 |
| ISIN | US66989HAK41 |
| Issuer | Novartis Capital Corp., United States |
| Guarantor | Novartis AG, Switzerland |
| Type | Senior unsecured |
| Coupon | 4.000% |
| Coupon payment date | May 20 and November 20, commencing May 20, 2016 |
| Documentation | SEC registered shelf registration |
| First settlement date | November 20, 2015 |
| Issue price | 98.029 |
| Maturity date | November 20, 2045 |
| Joint book-runners | Bank of America Merrill Lynch, Citi, JP Morgan, Credit Suisse, Goldman Sachs, UBS |
| Bloomberg | NOVNVX 4 11/20/2045 |